LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
LB Pharmaceuticals appoints Christopher Zergebel as Senior Vice President, Clinical Operations, to lead execution of clinical programs for LB-102, a novel neuropsychiatric drug candidate. Active Phase 3 and Phase 2 trials for schizophrenia, bipolar depression, and major depressive disorder signal strategic advancement in their pipeline.